DDX53 and neoplasm: To ascertain whether the R-337-infected tumor cells subjected to immunogenic death plus the IL-12 adjuvant conferred long-term distant protection, i.e., vaccinated mice against the tumor, the mice that survived the primary tumor received distant challenge tumors made of CT26-HER2 and, later, of CT26-wt cells.